drugset / Trial / NCT04939272
Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Phase 1/2
Active not recruiting
8 enrolled
City of Hope Medical Center
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
This phase I/II trial studies the side effects, best dose, and effectiveness of copanlisib and venetoclax in treating patients with mantle cell lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Copanlisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Venetoclax may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving copanlisib and venetoclax may help treat patients with mantle cell lymphoma.
Timeline
- Start
- 2022-06-29
- Primary completion
- 2027-02-12
- Completion
- 2027-02-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Copanlisib | Small molecule | 30 mg | Intravenous |
| Subject | Copanlisib | Small molecule | 45 mg | Intravenous |
| Subject | Copanlisib | Small molecule | 60 mg | Intravenous |
| Subject | Venetoclax | Small molecule | 400 mg | Oral |